Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals, Inc.) – In-Depth Analysis of the 2025 10-K/A Amendment No. 1

Key Highlights

• Company Name Change & Reverse Stock Split: The company has changed its name from Enzon Pharmaceuticals, Inc. to Viskase Holdings, Inc. and implemented a 1-for-100 reverse stock split on March 24, 2026. As a result, as of April 29, 2026, there are approximately 14,331,620 shares of Common Stock outstanding.
• Amendment Filing: This filing is an Amendment No. 1 to the previously filed 2025 Annual Report (Form 10-K), specifically to provide the Part III information (Items 10-14) that was omitted in the original filing. No financial statements are included or amended in this filing.
• Board & Governance Changes: The company details its current board and executive officers, board structure, committee membership, and governance practices. Notably, the company did not hold an annual general meeting in 2025 and does not require directors to attend annual meetings.
• Executive Compensation: All compensation to the CEO/CFO/Secretary, Richard L. Feinstein, was paid as consulting fees – no base salary. The company did not grant any equity awards or options in 2025 and does not currently maintain any equity compensation plans.
• Merger Activity: There are references to a significant merger that closed on March 26, 2026, with board and officer changes resulting from this event. The Special Committee, formed in January 2025, was tasked with negotiating and approving merger-related transactions.
• Related Party Transaction Policy: Any related party transactions require approval by the Finance and Audit Committee or a comparable committee of disinterested directors. The Special Committee was formed specifically to address conflicts regarding the merger.
• Audit & Financial Controls: The Finance and Audit Committee, composed of independent directors, monitored financial reporting, internal controls, and auditor independence. Audit fees for 2025 were \$126,000, paid to EisnerAmper LLP.
• Insider Trading & Hedging Policies: The company maintains robust insider trading and anti-hedging/pledging policies covering all directors, officers, employees, and temporary insiders. No violations or exceptions were disclosed.
• Regulatory Compliance: The company certified compliance with all SEC reporting, interactive data (XBRL) submissions, and Sarbanes-Oxley requirements. No internal control auditor attestation or error corrections/restatements were reported in this amendment.
• Listing Status: The company’s Common Stock is no longer listed on Nasdaq, and there are no securities registered under Section 12(b). All remaining shares are registered under Section 12(g).

Detailed Analysis and Shareholder-Relevant Developments

1. Corporate Structure & Share Capital

The company has undergone a name change and a 1-for-100 reverse stock split. This is a major development for shareholders as it dramatically reduces the number of shares outstanding and may affect liquidity and pricing. Such corporate actions are often intended to improve the company’s capital structure or meet listing requirements (though the company is no longer Nasdaq-listed). The reverse split may signal strategic repositioning or preparation for M&A activity.

Outstanding shares as of April 29, 2026: 14,331,620 shares post-reverse split.

2. Merger and Board/Executive Changes

The filing references a Merger transaction closed on March 26, 2026, which resulted in significant changes to the board and executive team. The Special Committee, composed of independent directors, was formed to manage potential conflicts of interest and ensure fairness in the merger process. Shareholders should note that:

• Richard L. Feinstein (CEO/CFO/Secretary) resigned as of the closing date.
• Other board members also resigned as of the closing, and the company’s governance structure may have changed post-merger.
• The full impact of the merger on strategy, operations, or financials is not detailed in this filing, but the governance changes are material and may influence investor confidence and future direction.

3. Executive Compensation

Richard L. Feinstein received all compensation as consulting fees—no base salary was paid for 2025 or 2024. For 2025, consulting fees totaled \$215,178, and total compensation was \$232,678. There were no equity grants, options, or bonus awards in 2025. This compensation structure is unusual for public companies and may reflect the company’s transitional status or financial strategy.

No equity compensation plans are currently in place, and the board does not plan to grant equity awards. This may impact the ability to attract and retain top talent.

4. Board Structure and Governance

The board, as of December 31, 2025, was composed of independent directors per Nasdaq standards, despite the company’s delisting. Board leadership is separated (Chairman and CEO roles are distinct), with the Chairman focusing on board oversight and the CEO on daily operations.

Standing Committees:

• Finance and Audit Committee: Monitored financial reporting, internal controls, and auditor independence. All members were independent, and at least one was a “financial expert.”
• Special Committee: Formed to handle merger negotiations and related party transactions.

Meetings: The board held 12 meetings during 2025; all directors attended at least 75% of meetings.

No annual general meeting was held in 2025. There is no policy requiring director attendance at AGMs.

5. Share Ownership and Related Party Transactions

Major Shareholders: As of April 29, 2026, tables show beneficial ownership of more than 5% by certain parties. Any changes in major shareholding post-merger could be price sensitive.

Related Party Transaction Policy: The company has a robust policy requiring any related party transactions to be approved by disinterested directors. The merger was handled by the Special Committee to address potential conflicts.

6. Regulatory & Compliance Matters

The company has complied with all SEC requirements, including timely filing of reports and XBRL submissions. There were no error corrections or restatements in this amendment, and no auditor attestation of internal controls was required due to the company’s status as a “smaller reporting company.”

Audit Fees: \$126,000 for 2025, paid to EisnerAmper LLP. No audit-related, tax, or other fees were reported.

7. Insider Trading, Hedging, and Corporate Policies

Insider Trading Policy: All officers, directors, employees, and temporary insiders are subject to the company’s insider trading policy. There were no violations or exceptions reported. The company prohibits hedging or pledging of company stock and holding company stock in margin accounts.

Code of Conduct: The Code of Conduct applies to all directors and executive officers. Any waivers or material changes are to be disclosed on the company website.

8. Potential Share Price Sensitivities

• The reverse stock split and reduction in shares outstanding may affect liquidity and trading dynamics.
• Merger activity and resulting board/executive changes could significantly impact the company’s strategic direction and valuation.
• The absence of equity compensation plans may affect talent retention and future growth prospects.
• Delisting from Nasdaq may impact liquidity, institutional ownership, and analyst coverage.
• The Special Committee’s handling of the merger and related party transactions may be scrutinized by investors, especially if further details are provided in future disclosures.

Conclusion

This amendment to the 2025 Form 10-K is primarily focused on updating governance, compensation, and ownership disclosures following a significant corporate transformation and merger event. These developments are material and may influence the company’s future direction, risk profile, and share price. Investors should closely monitor subsequent filings for more details on the merger, new board and executive composition, and strategic plans post-transaction.

Disclaimer

This article is for informational purposes only. It does not constitute investment advice or an offer to buy or sell any securities. Investors should conduct their own research and consult with professional advisors before making investment decisions. The information herein is based on the 2025 10-K/A Amendment No. 1 filing and may not reflect subsequent events or filings. The author and publisher assume no responsibility or liability for any errors or omissions or for any actions taken based on the information provided.

View Viskase Holdings, Inc. Historical chart here